These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344 [TBL] [Abstract][Full Text] [Related]
12. Repeatability of Quantitative Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729 [TBL] [Abstract][Full Text] [Related]
13. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739 [TBL] [Abstract][Full Text] [Related]
14. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer. Al Jalali V; Wasinger G; Rasul S; Grubmüller B; Wulkersdorfer B; Balber T; Mitterhauser M; Simon J; Hacker M; Shariat S; Egger G; Zeitlinger M J Nucl Med; 2023 Jun; 64(6):863-868. PubMed ID: 36657982 [TBL] [Abstract][Full Text] [Related]
15. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024 [TBL] [Abstract][Full Text] [Related]
16. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970 [TBL] [Abstract][Full Text] [Related]
17. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. Gorin MA; Marashdeh W; Ross AE; Allaf ME; Pienta KJ; Pomper MG; Rowe SP Nucl Med Commun; 2017 Sep; 38(9):795-798. PubMed ID: 28704341 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
19. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635 [TBL] [Abstract][Full Text] [Related]
20. Reproducibility and Repeatability of Semiquantitative Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121 [No Abstract] [Full Text] [Related] [Next] [New Search]